YMYuben Moodley

Yuben Moodley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuben Moodley has a total of 336 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monocyte IL-8 Levels are Associated with Early Mortality in Idiopathic Pulmonary Fibrosis

    by Dino B.A. Tan, Maike Stentenbach, Erick J. Aresgado, Chantalia Tedja, Wendy A. Cooper, Helen E. Jo, Christopher Grainge, Ian N. Glaspole, Nicole Goh, Samantha Ellis, et al.

    Extract Idiopathic pulmonary fibrosis (IPF) is progressive disease with a median survival 3–5 years post diagnosis in untreated patients [1]. Risk factors for mortality include gender, age of presentation and the severity of lung function abnormality. In addition, a high circulating monocyte count (≥0.95×106 cells·L−1) is also associated with increased mortality, though the mechanisms underpinning this phenomenon is still unclear [2, 3].

  • Open Access

    Deep‐Learning Algorithm Diagnostic Support for Usual Interstitial Pneumonia Pattern Recognition in Fibrotic Interstitial Lung Disease

    by Caitlin C Fermoyle, John A Mackintosh, Vidya Navaratnam, Samantha J Ellis, Wendy A Cooper, Nicole S L Goh, Yuben Moodley, Paul N Reynolds, Christopher J Zappala, Peter Hopkins, et al.

    Background and Objective: High resolution computed tomography (HRCT) scan diagnostic classification for usual interstitial pneumonia (UIP) plays a critical role in therapeutic decision‐making and clinical trial eligibility for interstitial lung disease (ILD) patients, but is subject to variability. A deep learning algorithm, the Systematic Objective Fibrotic Imaging Analysis Algorithm (SOFIA), has been validated to assist classification of HRCTs based on current guidelines. In this study, we evaluate the impact of SOFIA on inter‐observer agreement for UIP classification and prognostic accuracy of clinicians' assessment of ILD HRCTs. Methods: Radiologists and pulmonologists (reviewers) were invited to evaluate 203 HRCTs from a national fibrotic ILD registry, scoring each of four UIP categories (definite UIP, probable UIP, indeterminate, or alternative diagnosis). SOFIA outputs were then provided, and reviewers were able to reevaluate their scores. Changes in interobserver agreement for UIP classification and prognostic accuracy were calculated. Results: Three hundred twelve reviewers (120 radiologists, 192 pulmonologists) from 49 countries evaluated 203 HRCT scans. Following SOFIA, inter‐observer diagnostic agreement improved for definite UIP from moderate to good (ICC pre = 0.54[0.50–0.60]; ICC post = 0.70[0.66–0.74]), and for probable UIP from fair to moderate (ICC pre = 0.30[0.27–0.35]; ICC post = 0.53[0.49–0.58]). Following SOFIA, there was improved prognostic accuracy for reviewers' definite UIP, probable UIP, and indeterminate scores (significant change in c‐index), and the proportion of reviewers whose probable UIP scores were significantly predictive of transplant‐free survival increased by 42%. Conclusion: Providing SOFIA algorithm output to clinicians reviewing HRCT scans improved diagnostic agreement and prognostic accuracy for fibrotic ILD. SOFIA may be a useful automated assistive tool to support improved diagnostic consistency.


  • Open Access

    Quantum Reservoir Computing with Neutral Atoms on a Small, Complex, Medical Dataset

    by Luke Antoncich, Yuben Moodley, Ugo Varetto, Jingbo Wang, Jonathan Wurtz, Jing Chen, Pascal Jahan Elahi, Casey R. Myers

    Biomarker-based prediction of clinical outcomes is challenging due to nonlinear relationships, correlated features, and the limited size of many medical datasets. Classical machine-learning methods can struggle under these conditions, motivating the search for alternatives. In this work, we investigate quantum reservoir computing (QRC), using both noiseless emulation and hardware execution on the neutral-atom Rydberg processor \textit{Aquila}. We evaluate performance with six classical machine-learning models and use SHAP to generate feature subsets. We find that models trained on emulated quantum features achieve mean test accuracies comparable to those trained on classical features, but have higher training accuracies and greater variability over data splits, consistent with overfitting. When comparing hardware execution of QRC to noiseless emulation, the models are more robust over different data splits and often exhibit statistically significant improvements in mean test accuracy. This combination of improved accuracy and increased stability is suggestive of a regularising effect induced by hardware execution. To investigate the origin of this behaviour, we examine the statistical differences between hardware and emulated quantum feature distributions. We find that hardware execution applies a structured, time-dependent transformation characterised by compression toward the mean and a progressive reduction in mutual information relative to emulation.

  • Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis

    by John A. Mackintosh, Simon L. F. Walsh, Mario Silva, Lucio Calandriello, Stephen M. Humphries, David A. Lynch, Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, et al.

    Background and Objectives: In fibrotic lung disease, radiological features of usual interstitial pneumonia (UIP) are associated with adverse outcomes. The aim of this study was to evaluate the likelihood of definite UIP on HRCT as a determinant of outcome in patients with pulmonary fibrosis . Methods: All available HRCT from the Australian IPF Registry (AIPFR) were retrospectively reviewed by two radiologists. The radiologists were asked to assign a likelihood (%) within each of the four ATS/ERS/JRS/ALAT 2018 UIP categories, summating to 100%, enabling them to not be constrained by a single UIP category (e.g., 5% definite UIP, 95% alternative to UIP). Likelihood of UIP was defined as the percentage likelihood score for the definite UIP category. Semi‐quantitative features were also estimated. Cox proportional hazards regression was performed to evaluate the prognostic utility of the likelihood scores. Results: HRCT was available for analysis in 515 patients. Median follow‐up of the cohort was 4.1 years (IQR 2.0–6.2 years). Median total ILD extent was 30% (IQR20‐45%), with traction bronchiectasis and honeycombing present in 96.3% and 45.4% of cases respectively, and all three variables were associated with worse transplant‐free survival. A pattern of definite or probable UIP was favoured in 26.4% and 32.4% of cases respectively. Likelihood of definite UIP was independently associated with both reduced transplant‐free survival (HR1.12, 95% CI 1.04–1.20; p = 0.002) and 12‐month progression (HR1.19, 95% CI 1.04–1.35; p = 0.009) and was superior to the ATS/ERS/JRS/ALAT 2018 guideline‐based categories for these associations. Conclusions: We demonstrate that estimation of the likelihood of definite UIP is strongly associated with transplant‐free survival and 12‐month disease progression.


  • The role of epigenetic regulation in idiopathic pulmonary fibrosis

    by Roger M. Li, Maike Stentenbach, Dino B. A. Tan, Herbert P. Ludewick, E. Hadyn Walters, Britt Clynick, Yuben P. Moodley

    Idiopathic pulmonary fibrosis (IPF) is a serious respiratory disease with a poor prognosis and limited treatments. IPF is characterized by accumulation of extracellular matrix, destruction of gas exchange units, and decline in lung function. The pathogenesis and underlying mechanisms are poorly understood although a combination of environmental and genetic factors is implicated. Epigenetic modifications represent a facet of gene regulation likely important to key pathways including transforming growth factor (TGF-β1) signaling, fibroblast-to-myofibroblast differentiation, epithelial-to-mesenchymal transition, cellular aging, and apoptosis. Methylation, acetylation, noncoding RNAs, telomere length, and G-quadruplexes have all been investigated with varying levels of progress but are certainly potential targets for drug development. This review discusses the underlying epigenetic biology of IPF, associated clinical applications, and potential novel treatments.


  • Let-7f-5p Has Antifibrotic Properties and Is Reduced in Circulatory Small Extracellular Vesicles in Progressive Idiopathic Pulmonary Fibrosis

    by Dino B A Tan, Maike Stentenbach, Erin Bolitho, Chantalia Tedja, Erick Aresgado, Ching-Hsien Chen, Angela Linderholm, Justin Oldham, Yuben Moodley, Aipfr

  • Open Access

    CaNO and eCO Might Be Potential Non-Invasive Biomarkers for Disease Severity and Exacerbations in Interstitial Lung Disease

    by Yuling Zhang, Faping Wang, Min Zhu, Yali Zhang, Linrui Xu, Liangyuan Li, Ping Li, Qibing Xie, Xiaoyan Lv, Jianqun Yu, et al.

    Background: Interstitial lung diseases (ILDs) often progress quickly and are associated with a poor prognosis. New noninvasive biomarkers to assist in the classification and prognostication of ILD are needed. Exhaled nitric oxide (FeNO), Cavity nitric oxide (CaNO), and carbon monoxide (eCO) are biomarkers of airway inflammation, widely used in respiratory inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). However, their value in ILD remains unclear. Objective: To evaluate the potential diagnostic and prognostic value of FeNO, CaNO, and eCO in ILD, and explore their integration into clinical practice. Methods: A total of 237 patients were recruited for the study, including 14 with idiopathic pulmonary fibrosis (IPF), 46 with interstitial pneumonia with autoimmune features (IPAF), 19 with mixed connective tissue disease–associated ILD (MCTD-ILD), 65 with polymyositis/dermatomyositis-associated ILD (PM/DM-ILD), 17 with rheumatoid arthritis-associated ILD (RA-ILD), 7 with systemic lupus erythematosus-associated ILD (SLE-ILD), 19 with Sjögren’s syndrome-associated ILD (SS-ILD), and 50 with systemic sclerosis-associated ILD (SSc-ILD). Multiple-flow FeNO and eCO analyses were performed in this population. The associations of these biomarkers with pulmonary function, acute exacerbations, and radiologic fibrosis classification were evaluated. Results: Patients with IPF exhibited significantly higher levels of FeNO at 50 mL/s (FeNO50) compared to those with connective tissue disease-associated ILD (CTD-ILD) and IPAF. Both CaNO and eCO were negatively correlated with pulmonary function parameters, particularly forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO). Receiver operating characteristic (ROC) curve analysis indicated that CaNO is a reliable biomarker for acute exacerbation, with an area under the ROC curve (AUC) of 0.8887, and a cutoff value of 6.35. Additionally, CaNO > 6.35 was associated with a relative risk (RR) of 12.87 for acute exacerbation (AE) compared to CaNO ≤ 6.35. Moreover, both CaNO and eCO levels were significantly higher in the fibrotic ILD group compared to the non-fibrotic group, with ROC analysis indicating AUCs of 0.7173 for CaNO and 0.6875 for eCO. Conclusions: FeNO, CaNO, and eCO can provide strong support for the early diagnosis and monitoring of ILD, especially with CaNO playing a crucial role in predicting acute exacerbations. Integrating these biomarkers into clinical practice can help doctors more accurately assess the progression of ILD and develop personalized treatment plans, ultimately improving the prognosis of ILD patients. Future research is needed to validate the effectiveness of these biomarkers in clinical management, facilitating their integration as standard tools for clinical monitoring.

  • Top Cited Papers
    Open Access

    Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement

    by Anna J. Podolanczuk, Gary M. Hunninghake, Kevin C. Wilson, Yet H. Khor, Fayez Kheir, Brandon Pang, Ayodeji Adegunsoye, Gretchen Cararie, Tamera J. Corte, Jim Flanagan, et al.

    Background: There is growing interest in identifying early stages of interstitial lung disease (ILD) to improve patient outcomes. This document reviews updated evidence on interstitial lung abnormalities (ILAs); provides suggestions for screening, evaluation, and management; proposes criteria for distinguishing ILAs from ILD; and identifies research priorities. Methods: A committee of clinical and methodology experts met by video conference to define ILAs and ILD by consensus and voted on 11 prespecified questions after reviewing synthesized evidence from a systematic literature search. Agreement of ≥70% was required to approve each suggestion. Results: ILA is defined as nondependent bilateral parenchymal abnormalities on computed tomography, including ground-glass opacities or reticulations, lung distortion, traction bronchiectasis, and/or honeycombing involving ≥5% of a lung zone. The updated definition removes the prior exclusion of high-risk populations. ILD is distinguished from ILAs by symptoms (dyspnea/cough) attributable to an interstitial process, abnormal or declining lung function, fibrotic (honeycombing and/or reticulation with traction bronchiectasis involving ≥5% of total lung volume) or progressive imaging abnormalities, and/or specific fibrotic ILD patterns on imaging or pathology. Suggestions include ILA/ILD assessment on imaging acquired for lung cancer screening, screening adults with connective tissue disease and first-degree relatives of patients with familial pulmonary fibrosis, assessing baseline symptoms and pulmonary function among those with ILAs, and monitoring ILAs with chest computed tomography every 2–3 years. Conclusions: This document presents a comprehensive literature review of ILAs with updates to the Fleischner Society ILA definition, establishes a working ILD definition, and provides evidence-based suggestions for ILA evaluation and management.


  • Open Access

    A Comprehensive Review of Interstitial Lung Abnormalities

    by Yuben Moodley, John A. Mackintosh

    Interstitial lung abnormalities (ILAs) represent radiological entities that comprise changes compatible with an interstitial process, occurring in individuals not suspected to have interstitial lung disease (ILD). The prevalence of ILAs ranges from 2.5% to 16.7% in lung cancer screening and population‐based cohorts. ILAs have consistently been associated with mortality. Risk factors include older age, smoking, and genetic polymorphisms such as MUC5B. Progression of ILAs occurs in 20%–76% of cases over 2–6 years of follow‐up. The clinical approach to ILAs involves risk stratification based on radiological features, extent of involvement, and associated clinical and physiological findings. ILAs pose a significant challenge in distinguishing inconsequential radiological findings from early ILD. This review summarises the current understanding of ILAs, including prevalence, risk factors, progression, associated biomarkers, and clinical management strategies.